Sign in to continue:

Sunday, February 8th, 2026

CapitaLand Investment Ltd (CLI) 2025 Outlook: Portfolio Optimisation, China REIT Listing & Growth Prospects Explained

Broker Name: Maybank Research Pte Ltd
Date of Report: November 13, 2025

Excerpt from Maybank Research Pte Ltd report.

Report Summary

  • CapitaLand Investment Ltd (CLI) is maintaining steady execution in its real estate investment business, focusing on portfolio optimisation and value unlocking. The company’s 9M25 business update highlights flat revenue year-on-year, with growth in fee-related income being offset by the loss of revenue from divested assets.
  • CLI raised SGD2.1 billion in external capital for private funds year-to-date and successfully listed CapitaLand Commercial C-REIT in China. The analyst maintains a BUY rating and raises the target price to SGD3.30, reflecting CLI’s strong fee business, ongoing capital recycling, and higher market value of listed funds. Risks include asset markdowns, slower fundraising, high funding costs, and global economic challenges.

Above is an excerpt from a report by Maybank Research Pte Ltd. Clients of Maybank Research Pte Ltd can be the first to access the full report from the Maybank website : https://www.maybank.com/investment-banking

Sunway REIT: Diverse Portfolio and Strong Growth Prospects Drive Investor Confidence

Date: October 2, 2024Broker: Maybank Investment Bank Berhad OverviewSunway REIT (SREIT MK) is one of Malaysia’s largest diversified REITs, with a portfolio spanning retail, office, hospitality, and industrial segments. Its assets are strategically located...

Grand Venture Technology: Riding the Semiconductor Boom with Strategic Diversification

The semiconductor industry’s resurgence is sparking optimism among market observers, and Grand Venture Technology (GVT) is emerging as a standout beneficiary. With strategic expansions, key contract wins, and diversification into high-growth areas, the Singapore-listed...

BeiGene Ltd (6160) Surges Amid Bullish Technicals: A Promising Investment Opportunity

Company HighlightsBeiGene Ltd (HKG: 6160) has recently emerged as a strong contender for investors looking for growth in the biopharmaceutical sector. As a commercial-stage company specializing in the discovery and commercialization of molecularly targeted...